{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:59:56Z","timestamp":1787237996049,"version":"build-2736575974"},"reference-count":21,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"MEC | Instituto de Salud Carlos III","award":["CP19\/00159"],"award-info":[{"award-number":["CP19\/00159"]}]},{"name":"MEC | Instituto de Salud Carlos III","award":["CM21\/00115"],"award-info":[{"award-number":["CM21\/00115"]}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Microbiol Spectr"],"published-print":{"date-parts":[[2024,8,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Real-life data on doravirine (DOR) in different drug combinations are limited. We evaluated the effectiveness of DOR plus two nucleos(t)ide reverse transcriptase inhibitors (NRTI), mainly abacavir\/lamivudine, and dual therapies in people with HIV (PWH), mostly virologically suppressed. Ambispective observational study that enrolled adults PWH who initiated a DOR-based regimen from September 2020 to February 2022 at a referral center in Spain. Participants were grouped as follows: A, received DOR plus two NRTI; B, dual therapy (DT) with DOR plus dolutegravir (DTG) or darunavir\/cobicistat (DRVc); C, DOR plus \u2265two antiretroviral drugs. The primary endpoints were treatment effectiveness at week 48 by intention-to-treat (ITT) and per-protocol analysis (OT). A cohort of 187 participants, 91% virologically suppressed, were analyzed after a median follow-up of 112 weeks (80\u2013136). Group A received DOR plus abacavir\/lamivudine (ABV\/3TC) (\n                      <jats:italic>n<\/jats:italic>\n                      = 109) or tenofovir\/emtricitabine (TFV\/3TC) (\n                      <jats:italic>n<\/jats:italic>\n                      = 45). At week 48, the effectiveness of DOR plus ABV\/3TC by ITT was 90.8% (CI\n                      <jats:sub>95<\/jats:sub>\n                      , 88.0\u201393.6), better than with TFV\/FTC [73.3% (66.7\u201379.9);\n                      <jats:italic>P<\/jats:italic>\n                      = 0.003]. Only one virologic failure was observed. Mild adverse effects were the cause of treatment discontinuation in 7.8%, followed by switching to a single-tablet regimen. In group B, the effectiveness by ITT was 92.9% (CI\n                      <jats:sub>95<\/jats:sub>\n                      , 88.0\u201397.8) at week 48. No adverse effects or virologic failure were registered in this group. DOR plus two NRTI or DT have long-term effectiveness and safety as a switching option for PWH, mostly virologically suppressed. The DOR plus ABV\/3TC combination has shown even better effectiveness than TFV\/FTC.\n                    <\/jats:p>\n                    <jats:sec>\n                      <jats:title>IMPORTANCE<\/jats:title>\n                      <jats:p>DOR-based regimens have shown long-term effectiveness and safety in PWH, mostly virologically suppressed. The combination of DOR plus ABV\/3TC has shown even better safety and effectiveness than TFV\/FTC. DOR plus two NRTI offers cost benefits compared to other regimens.<\/jats:p>\n                    <\/jats:sec>\n                  <\/jats:sec>","DOI":"10.1128\/spectrum.00654-24","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T09:01:32Z","timestamp":1719306092000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":5,"title":["Long-term effectiveness, safety, and tolerability of doravirine in antiretroviral-experienced people with HIV in real life"],"prefix":"10.1128","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3819-4966","authenticated-orcid":false,"given":"Marta","family":"Mej\u00edas-Trueba","sequence":"first","affiliation":[{"name":"Department of Pharmacy, University Hospital Virgen del Roc\u00edo, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Gutierrez-Valencia","sequence":"additional","affiliation":[{"name":"Infectious Diseases and Microbiology Clinical Unit. Instituto de Biomedicina de Sevilla\/University Hospital Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla, Sevilla, Spain"},{"name":"Primary Care Pharmacist Service, Sevilla Primary Care District, Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Llaves-Flores","sequence":"additional","affiliation":[{"name":"Infectious Diseases and Microbiology Clinical Unit. Instituto de Biomedicina de Sevilla\/University Hospital Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla, Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Roca-Oporto","sequence":"additional","affiliation":[{"name":"Infectious Diseases and Microbiology Clinical Unit. Instituto de Biomedicina de Sevilla\/University Hospital Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla, Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Herrero","sequence":"additional","affiliation":[{"name":"Infectious Diseases and Microbiology Clinical Unit. Instituto de Biomedicina de Sevilla\/University Hospital Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla, Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9sar","family":"Sotomayor de la Piedra","sequence":"additional","affiliation":[{"name":"Infectious Diseases and Microbiology Clinical Unit. Instituto de Biomedicina de Sevilla\/University Hospital Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla, Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3804-3458","authenticated-orcid":true,"given":"Luis F.","family":"Lopez-Cortes","sequence":"additional","affiliation":[{"name":"Infectious Diseases and Microbiology Clinical Unit. Instituto de Biomedicina de Sevilla\/University Hospital Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla, Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Espinosa","sequence":"additional","affiliation":[{"name":"Infectious Diseases and Microbiology Clinical Unit. Instituto de Biomedicina de Sevilla\/University Hospital Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla, Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_3_2","unstructured":"European AIDS Clinical Society. EACS guidelines version 12. Available from: https:\/\/www.eacsociety.org\/media\/guidelines-12.0.pdf. Retrieved 24 Oct 2023. 24 Oct 2023"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa822"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30336-4"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002056"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky464"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa009"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz553"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000029855"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1089\/AID.2022.0058"},{"key":"e_1_3_3_12_2","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. 2023. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available from: https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/adult-adolescent-arv\/guidelines-adult-adolescent-arv.pdf\/. Retrieved 19 Oct 2023."},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0171155"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0205777"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1177\/09564624231195084"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002730"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.846943"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkad240"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-023-00503-5"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000028488"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000003248"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1177\/09564624221116533"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-023-02075-y"}],"container-title":["Microbiology Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.00654-24","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.00654-24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T09:20:22Z","timestamp":1722936022000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/spectrum.00654-24"}},"subtitle":[],"editor":[{"given":"Jose","family":"Martinez-Navio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,8,6]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8,6]]}},"alternative-id":["10.1128\/spectrum.00654-24"],"URL":"https:\/\/doi.org\/10.1128\/spectrum.00654-24","relation":{},"ISSN":["2165-0497"],"issn-type":[{"value":"2165-0497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,6]]},"assertion":[{"value":"2024-04-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00654-24"}}